What top creators are saying about Humacyte, Inc.(HUMA)
Biotechnology company.
12 AI-extracted insights from 4 sources — podcasts, YouTube channels, and X/Twitter accounts.
Creator sentiment — last 30 days
Based on 6 scored insights about Humacyte, Inc..
The Take
Coverage was mostly bearish to mixed: sources acknowledged promising interim Phase 3 results and growing hospital use, but centered on weak revenue and uncertainty about adoption, product advantage, and sustained demand. Humacyte (HUMA) was also cited as down approximately 60% year to date.
Bull Case
- Interim Phase 3 results: Supporters cited positive interim results as a reason to remain invested. (per Shkreli Planet, The Shkreli Pill, Martin Shkreli)
- Hospital adoption: Reported hospitals using ATEV increased from 34 to 49, with one investor viewing adoption growth as encouraging. (per Shkreli Planet, Martin Shkreli)
- Potential commercial growth: Revenue rose to about $400,000 from $100,000 previously, though sources did not establish whether growth would continue. (per Shkreli Planet)
Bear Case
- Weak commercial demand: Reported revenue remained low, prompting doubts about demand and commercial traction. (per The Shkreli Pill, Martin Shkreli)
- Uncertain adoption and repeat use: Sources questioned whether hospitals would adopt the product broadly and use it repeatedly. (per Shkreli Planet, Martin Shkreli)
- Product and trial concerns: Skeptics questioned clinical superiority, product performance, shelf life, and distribution. (per Martin Shkreli, Shkreli Planet)
- Share-price weakness: HUMA was cited among steep year-to-date decliners, down approximately 60%. (per Shkreli Planet)
Catalysts & Targets
- Latest-quarter revenue: about $400,000, up from $100,000 previously.
- Hospitals using ATEV reportedly increased from 34 to 49.
- Year-to-date share-price decline cited at approximately 60%.
AI-generated summary. Not investment advice. Learn more.
Top creators covering Humacyte, Inc. (HUMA)
The 4 sources with the most insights about Humacyte, Inc. on Kazuha.
Latest insights about Humacyte, Inc. (HUMA)
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Wednesday, November 4, 2026
Cited among steep year-to-date decliners at approximately 60% down; the discussion did not provide a company-specific investment thesis.
Monday, November 2, 2026
An investor remains long based on positive interim Phase 3 results and growth in hospitals using ATEV, while a skeptic questions its clinical advantage, hospital adoption, and ability to generate durable sales. Revenue was reported at $400,000 in the latest quarter, up from $100,000 previously; sustained revenue growth and repeat use are key uncertainties.
Thursday, October 29, 2026
Interim Phase 3 results were described as promising, but low revenue and uncertain hospital adoption prompted concerns about commercial demand.
Tuesday, October 27, 2026
Views were sharply divided: one speaker remained invested based on interim Phase 3 results, while another questioned demand, commercial traction, product advantages, and the durability of potential overseas interest.
Monday, October 26, 2026
Positive interim Phase 3 results were noted, but concerns about weak commercial demand, product performance, shelf life, and distribution made the overall discussion mostly bearish. Revenue was about $400,000 and the number of hospitals using the product reportedly rose from 34 to 49.
The guest was long and cited Phase 3 results and hospital growth, but the speaker was highly skeptical about trial superiority, hospital adoption, end-user demand, and very low reported revenue.
Wednesday, November 12, 2025
The speaker is bearish and was shorting the stock, highlighting a significant valuation concern where the company generated only $700k in revenue with a market cap of around $250 million.
Tuesday, October 28, 2025
The speaker is bearish, mocking the company for an 'oversubscribed deal for warrants' and suggesting it's a sign of weakness.
Thursday, August 21, 2025
The CEO made a large, unscheduled sale of $3.7 million. Following the CEO's previous sales, the stock has fallen an average of 15%.
Wednesday, August 13, 2025
Monday, August 11, 2025
The speaker is extremely bearish, calling the company a 'dog' and a 'whole disaster.' This is due to extremely weak revenue ('less than a million'), with no reason seen for the stock to rebound.
Tuesday, July 29, 2025
Listed as one of the speaker's biggest losing positions, which came from a short position he was holding.
Wednesday, November 4, 2026
Cited among steep year-to-date decliners at approximately 60% down; the discussion did not provide a company-specific investment thesis.
Monday, November 2, 2026
An investor remains long based on positive interim Phase 3 results and growth in hospitals using ATEV, while a skeptic questions its clinical advantage, hospital adoption, and ability to generate durable sales. Revenue was reported at $400,000 in the latest quarter, up from $100,000 previously; sustained revenue growth and repeat use are key uncertainties.
Thursday, October 29, 2026
Interim Phase 3 results were described as promising, but low revenue and uncertain hospital adoption prompted concerns about commercial demand.
Tuesday, October 27, 2026
Views were sharply divided: one speaker remained invested based on interim Phase 3 results, while another questioned demand, commercial traction, product advantages, and the durability of potential overseas interest.
Monday, October 26, 2026
Positive interim Phase 3 results were noted, but concerns about weak commercial demand, product performance, shelf life, and distribution made the overall discussion mostly bearish. Revenue was about $400,000 and the number of hospitals using the product reportedly rose from 34 to 49.
The guest was long and cited Phase 3 results and hospital growth, but the speaker was highly skeptical about trial superiority, hospital adoption, end-user demand, and very low reported revenue.
Wednesday, November 12, 2025
The speaker is bearish and was shorting the stock, highlighting a significant valuation concern where the company generated only $700k in revenue with a market cap of around $250 million.
Tuesday, October 28, 2025
The speaker is bearish, mocking the company for an 'oversubscribed deal for warrants' and suggesting it's a sign of weakness.
Thursday, August 21, 2025
The CEO made a large, unscheduled sale of $3.7 million. Following the CEO's previous sales, the stock has fallen an average of 15%.
Wednesday, August 13, 2025
Monday, August 11, 2025
The speaker is extremely bearish, calling the company a 'dog' and a 'whole disaster.' This is due to extremely weak revenue ('less than a million'), with no reason seen for the stock to rebound.
Tuesday, July 29, 2025
Listed as one of the speaker's biggest losing positions, which came from a short position he was holding.
Discussed alongside Humacyte, Inc. (HUMA)
Other assets that creators frequently mention in the same content as Humacyte, Inc..
Frequently asked
Are top creators bullish or bearish on Humacyte, Inc. (HUMA) right now?
Mostly bearish. In the last 30 days, 0 insights were bullish, 4 bearish, and 2 neutral about Humacyte, Inc. (HUMA) across 4 financial sources indexed on Kazuha.
Which podcasters and creators cover Humacyte, Inc. (HUMA) the most?
The most active sources covering Humacyte, Inc. (HUMA) on Kazuha are @realmartinshkreli, @shkreliplanet, @ceowatcher, @theshkrelipill. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
How many insights about Humacyte, Inc. (HUMA) are on Kazuha?
Kazuha has indexed 12 AI-extracted insights about Humacyte, Inc. (HUMA) from 4 different sources. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
What other assets do creators discuss alongside Humacyte, Inc. (HUMA)?
Creators covering Humacyte, Inc. (HUMA) most frequently also discuss NVDA, RKLB, IONQ, PLTR, NLST. See the "Discussed alongside" section above for full asset pages.